Penumbra Q3 2026 Earnings: Revenue Rises 15.6% as EPS Declines

Penumbra (NYSE: PEN) reported Q3 2026 revenue of $410.1 million, up 15.6% from $354.7 million a year earlier, while diluted EPS fell to $1.07 from $1.17. Thrombectomy and U.S. sales led growth, but operating expenses increased faster than revenue and a higher tax provision contributed to lower net income.

Core Financial Results

Gross profit grew slightly faster than revenue, lifting gross margin by 0.5 percentage points to 68.3%. However, operating expenses rose approximately 19.8%, limiting operating income growth to about 3.9% and reducing operating margin.

Operating expenses included $25.4 million of research and development costs and $204.2 million of selling, general and administrative expenses. SG&A included $7.1 million of costs related to the pending acquisition by Boston Scientific.

Business and Segment Performance

Thrombectomy remained Penumbra’s main growth engine, accounting for about 68% of quarterly revenue and approximately 77% of the company’s year-over-year revenue increase. U.S. revenue also expanded more than twice as fast as international revenue.

Within the U.S. business, venous thromboembolism revenue increased 26.0%. U.S. neuro revenue reached $77.9 million, up 19.3%, providing another source of domestic growth.

Cash, Investments, and Inventory

Penumbra ended September with $254.3 million in cash and cash equivalents and $419.3 million in marketable investments. Their combined value was approximately $673.6 million, up from $544.8 million at the end of December 2025.

Inventory increased to $459.1 million from $431.5 million over the same period, while accounts receivable rose to $195.2 million from $190.0 million. The release did not include a cash-flow statement, so the sources of the increase in cash and investments cannot be determined from the disclosed quarterly materials.

Faster Expense Growth Offset Revenue and Gross-Margin Gains

The central earnings issue was the gap between revenue growth and expense growth. Although revenue increased 15.6% and gross margin improved, total operating expenses rose by approximately $38.0 million, or 19.8%. The $7.1 million acquisition-related charge accounted for part, but not all, of that increase.

The higher expense base left operating income only modestly above the prior-year level. In addition, the income tax provision increased to $14.0 million from $6.5 million even as pretax income rose to $56.3 million from $52.3 million. The resulting effective tax rate was about 24.9%, compared with approximately 12.4% a year earlier, helping explain why net income and EPS declined despite revenue and operating income growth. Penumbra did not provide a reason for the higher tax rate in the release.

Pending Acquisition Adds Costs and Limits Forward Visibility

Penumbra’s pending acquisition by Boston Scientific affected both expenses and financial disclosure. The company recorded $7.1 million in acquisition-related costs during the quarter and declined to provide full-year 2026 guidance or host a quarterly conference call because of the transaction.

As a result, investors do not have an updated standalone quantitative outlook for Penumbra’s revenue, profitability, or expenses beyond the reported quarter. The timing and receipt of required regulatory approvals also remain relevant to completion of the transaction.

Risks Investors Need to Watch

• Operating expense growth: Expenses grew faster than revenue in Q3, compressing operating margin even as gross margin improved. Continued SG&A growth could limit the conversion of sales growth into earnings.
• Acquisition uncertainty and disruption: The Boston Scientific transaction remains pending and requires regulatory approvals. Penumbra also identified potential employee departures and management distraction during the process.
• Concentration of growth: U.S. revenue grew 17.9% versus 7.8% internationally, while thrombectomy generated most of the incremental revenue. Slower performance in these leading areas would have an outsized effect on total growth.
• Inventory levels: Inventory rose approximately 6.4% from December 2025 to $459.1 million. Its future use and conversion into sales remain important balance-sheet items to monitor.
• Tax-rate variability: A higher tax provision was a major reason net income declined despite higher operating profit. The company did not explain whether the Q3 effective tax rate was temporary or likely to persist.

Summary

Penumbra’s Q3 2026 results showed continued double-digit revenue growth led by thrombectomy, U.S. VTE, and neuro products, along with a modest improvement in gross margin. Those gains did not fully reach the bottom line because operating expenses grew faster than revenue and the tax provision increased sharply. The pending Boston Scientific acquisition now shapes both the cost structure and the limited forward visibility, making expense control, tax levels, inventory, and transaction progress the main items to monitor.